Renascience

Renascience CapEx/D&A

The CapEx to Depreciation Ratio of Renascience (4889.T) as of Nov 19, 2026 is 12.89. In the previous year, CapEx to Depreciation Ratio was 0.86 — a change of 1,401.18% (higher).

CapEx/D&A

12.89

YoY

1,401.18%

Last updated:

CapEx to Depreciation Ratio of Renascience is 2025 12.89 . CapEx to Depreciation Ratio of Renascience was 2024 0.86 . It decreases by 1,401.18% higher compared to the previous year.

The Renascience CapEx/D&A history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/D&A
Date
CapEx/D&A
Jan 1, 2020
0.00 JPY
Jan 1, 2021
0.35 JPY
Jan 1, 2022
0.38 JPY
Jan 1, 2023
1.61 JPY
Jan 1, 2024
0.86 JPY
Jan 1, 2025
12.89 JPY
The Renascience CapEx/D&A history
YEARCapEx/D&AYoY
12.89+1,401.18%
0.86-46.83%
1.61+326.41%
0.38+7.52%
0.35—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

CapEx to Depreciation Ratio of Renascience is 12.89 in 2025.

CapEx to Depreciation Ratio of Renascience changed from 0.86 to 12.89, representing a 1,401.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio Renascience since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's Renascience with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Renascience

All Key Metrics — Renascience